Licarbazepine information

Licarbazepine
	Top: (R)-(−)-licarbazepine; Bottom: (S)-(+)-licarbazepine
Clinical data
ATC code	None;
Pharmacokinetic data
Protein binding	<40%
Metabolites	Glucuronides
Excretion	Mainly renal
Identifiers
	IUPAC name (RS)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide;
CAS Number	29331-92-8;
PubChem CID	114709;
ChemSpider	102704;
UNII	XFX1A5KJ3V;
KEGG	D09215;
ChEMBL	ChEMBL1067;
CompTox Dashboard (EPA)	DTXSID50865484 ;
ECHA InfoCard	100.122.427
Chemical and physical data
Formula	C15H14N2O2
Molar mass	254.289 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES NC(=O)N1c2ccccc2CC(O)c3ccccc13;
	InChI InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19); Key:BMPDWHIDQYTSHX-UHFFFAOYSA-N;

Licarbazepine is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects that is related to oxcarbazepine.^[1] It is an active metabolite of oxcarbazepine.^[1]^[2] In addition, an enantiomer of licarbazepine, eslicarbazepine ((S)-(+)-licarbazepine), is an active metabolite of eslicarbazepine acetate.^[1]^[2] Oxcarbazepine and eslicarbazepine acetate are inactive on their own, and behave instead as prodrugs to licarbazepine and eslicarbazepine, respectively, to produce their therapeutic effects.^[1]^[2]

^ ^a ^b ^c ^d Singh RP, Asconapé JJ (2011). "A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy". Journal of Central Nervous System Disease. 3: 179–87. doi:10.4137/JCNSD.S4888. PMC 3663619. PMID 23861647.
^ ^a ^b ^c Bialer M, Soares-da-Silva P (June 2012). "Pharmacokinetics and drug interactions of eslicarbazepine acetate". Epilepsia. 53 (6): 935–46. doi:10.1111/j.1528-1167.2012.03519.x. PMID 22612290. S2CID 21233948.

[pmid23861647-1] Singh RP, Asconapé JJ (2011). "A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy". Journal of Central Nervous System Disease. 3: 179–87. doi:10.4137/JCNSD.S4888. PMC 3663619. PMID 23861647.

[pmid22612290-2] Bialer M, Soares-da-Silva P (June 2012). "Pharmacokinetics and drug interactions of eslicarbazepine acetate". Epilepsia. 53 (6): 935–46. doi:10.1111/j.1528-1167.2012.03519.x. PMID 22612290. S2CID 21233948.

Licarbazepine information

and 29 Related for: Licarbazepine information

Licarbazepine

Oxcarbazepine

Eslicarbazepine acetate

Cocaine

Ketamine

Calcium channel blocker

Gabapentin

Promethazine

Chlorphenamine

Lidocaine

Cholesterol

Kava

Pregabalin

Propranolol

Phenibut

Meclizine

Domperidone

Buprenorphine

Benzocaine

Amitriptyline

Lorazepam

Barbiturate

Diphenhydramine

Baclofen

Carbamazepine

Benzonatate

Pethidine

Valproate

Topiramate

Clinical data
Top: (R)-(−)-licarbazepine Bottom: (S)-(+)-licarbazepine
ATC code	None
Pharmacokinetic data
Protein binding	<40%
Metabolites	Glucuronides
Excretion	Mainly renal
Identifiers
IUPAC name (RS)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
CAS Number	29331-92-8
PubChem CID	114709
ChemSpider	102704
UNII	XFX1A5KJ3V
KEGG	D09215
ChEMBL	ChEMBL1067
CompTox Dashboard (EPA)	DTXSID50865484
ECHA InfoCard	100.122.427
Chemical and physical data
Formula	C₁₅H₁₄N₂O₂
Molar mass	254.289 g·mol⁻¹
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES NC(=O)N1c2ccccc2CC(O)c3ccccc13
InChI InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19) Key:BMPDWHIDQYTSHX-UHFFFAOYSA-N